Ecolab Inc (ECL) | The Buildout — AI Infrastructure
The Verdict
Ecolab supplies water treatment, hygiene, and infection-prevention products and services. Through Global High-Tech, it provides ultra-pure water for chip fabs and direct-to-chip liquid cooling for data centers, with digital monitoring layered across both. Its role in the AI buildout is physical: AI chips need water to be produced, powered, and cooled, and Ecolab is assembling that chain into one integrated offering.
| Market Cap | — |
| Revenue (TTM) | $16.8B |
| Revenue Growth | +7.1% |
| EBITDA Margin (TTM) | 20.1% |
| Net Debt | $8.6B |
| Earnings Beats | 2 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Global High-Tech grew 29% in Q2; management attributed it to demand from microelectronics and data centers driven by the AI infrastructure buildout.
- CoolIT pre-acquisition YTD growth was more than 100%, while management's planning assumption remains 30%.
- Management raised the Global High-Tech 2030 target to more than 25% annual growth, $4 billion sales, and 25% operating income margin.
- Life Sciences grew 15% in Q2 with mid-20s Q2 operating income margin, and the China purification plant opened weeks ago.
- Core businesses improved: Food & Beverage +7%, and Paper turned positive for the first time in more than a year.
What We’re Watching
- CoolIT integration closed July 2, 2026; the long-term model update is deferred to November 17.
- Middle East customer disruptions were about a 1% volume headwind in Q2 and may continue.
- Commodity costs are expected high-single-digit through 2026; 5–6% pricing must hold.
- Life Sciences Q3 reported operating income margin is guided to high-teens versus mid-20s underlying.
The thesis is strengthening on the supplied evidence: growth engines accelerated, commodity costs were absorbed in one quarter, and long-term high-tech targets were raised. The open question is whether CoolIT can keep growing far above the unchanged 30% planning case once integrated.
Earnings
For Q2 2026, reported sales were $4.4 billion, up 10% year over year, with organic sales up 5% on 4% pricing and 1% volume. Volume included about a 1% Middle East disruption headwind. Adjusted diluted EPS was $2.09, up 11%, and reported diluted EPS was $1.90. Organic gross margin was stable through higher commodity costs.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $4.4B | $4.1B | $4.0B | +9.7% |
| Gross margin | 44.1% | 43.6% | 44.8% | -70bps |
| EBITDA | $758M | $885M | $952M | −20.4% |
| EPS | $1.89 | $1.52 | $1.84 | +2.9% |
| Global High-Tech growth | +29% | >20% organic (Q1) | n/a | — |
| CoolIT YTD growth prior to acquisition | >100% | close to triple-digit range (Q1) | n/a | — |
Every time that the new generation of chips coming.. you change all the system for the direct-to-chip cooling, which means new cold plates, new coolant and as the power demand goes up, you change the CDUs as well at the same time. So it's inherently a recurring business.— Chief Executive Officer, July 28, 2026
Management tone: Management's tone broadened from Q1's focus on cost absorption and pricing to Q2's growth and portfolio shift. The CEO said Life Sciences is "finally where we were hoping to be," said to expect "good news in November" on high-tech, and called himself "cautiously optimistic" on Paper.
Management Guidance
For 2026, management raised adjusted diluted EPS guidance to $8.05–$8.25, up 7% to 10%, now including short-term noncash amortization and financing costs from CoolIT. Second-half organic sales are guided to 6–7%, adjusted operating income margin to approximately 19%, and pricing to 5–6%. Beyond 2026, adjusted EPS growth including CoolIT is expected to accelerate back to 12–15%.
Trajectory
Reported quarterly sales moved from $4.1 billion in Q1 to $4.4 billion in Q2, an 8.6% sequential step up, as acquisitions and pricing layered onto stable volume. Organic growth improved from 4% in Q1 to 5% in Q2, and pricing exited Q2 at 5%. Gross margin stayed stable through higher commodity costs, while reported operating and EBITDA margins are being compressed by the Ovivo acquisition mix and CoolIT amortization.
The Model
The model projects FY+1 revenue of $17,870 million with EBITDA of $4,468 million, a 25.0% margin, and FY+2 revenue of $20,000 million with EBITDA of $5,240 million, a 26.2% margin. The near-term path is anchored by 2H 2026 organic growth of 6–7% and the acquisitions of Ovivo and CoolIT; FY+2 assumes the growth-engine mix keeps shifting toward faster-growing lines and the acquisitions contribute a full year.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $16.1B | $17.9B | $20.0B |
| YoY Growth | — | +11.1% | +11.9% |
| EBITDA | $3.5B | $4.5B | $5.2B |
| EBITDA Margin | 21.9% | 25.0% | 26.2% |
Projections are the median of 5 independent model runs. The model’s revenue sits 4.5% above analyst consensus.
For 2026, management raised adjusted diluted EPS guidance to $8.05–$8.25, up 7% to 10%, now including short-term noncash amortization and financing costs from CoolIT. Second-half organic sales are guided to 6–7%, adjusted operating income margin to approximately 19%, and pricing to 5–6%. Beyond 2026, adjusted EPS growth including CoolIT is expected to accelerate back to 12–15%.
What Could Go Right — and Wrong
- CoolIT's actual growth keeps well above the 30% planning case, and the November update raises 2027+ targets again.
- The integrated CoolIT plus 3D TRASAR platform becomes the standard data-center cooling loop, pulling Ecolab into full-loop outcomes rather than components.
- The April 2026 energy surcharge converts into structural pricing, keeping second-half pricing at 5–6% after commodities normalize.
- Life Sciences sustains double-digit growth and moves toward its 30% long-term operating income margin as three-continent capacity fills.
- Digital expands from the near-$500 million run rate toward the disclosed $3 billion same-customer target, plus the incremental $10 billion beyond current customers.
- CoolIT growth normalizes toward 30% or below once the pre-acquisition surge laps, undermining the $4 billion 2030 high-tech target.
- Competitors in data-center thermal management, including Vertiv, Eaton, Modine, and Dover, compress Ecolab's early lead and pricing.
- Commodity costs stay high-single-digit while the surcharge pricing rolls back, squeezing gross margin in 2H 2026 and 2027.
- Middle East disruption or softer restaurant and industrial demand drags the core business that is still the majority of sales.
- CoolIT's amortization and financing costs outrun its growth, and Nalco amortization roll-off is not enough to hold the 20% 2027 operating income margin.
Looking Ahead
The next two checkpoints are Q3 earnings and the November 17, 2026 Supercomputing Chicago event and Investor Day. The first tests second-half pricing, organic sales, and Paper; the second is where management plans to launch the integrated cooling platform and update the CoolIT and high-tech model.
- Q3 2026Q3 2026 earnings — Tests 2H pricing 5–6%, organic sales 6–7%, Life Sciences margin, Paper trajectory.
- November 17, 2026Supercomputing Chicago Investor Day — Integrated cooling platform launch; updated CoolIT and high-tech model.
- End 20261 million Pest devices — Connected device count is a checkable commitment.
- 2027FY27 guidance / results — Tests 20% OI margin, growth engines ~25% of sales, EPS 12–15%.
- 2028ROIC recovery — Organic ROIC expected back to pre-CoolIT acquisition levels.
- 2030Global High-Tech $4B target — Tests >25% growth, $4B sales, 25% OI margin.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $15.7B | $16.1B | $16.8B | +2.2% |
| Gross Margin | 43.5% | 44.5% | 44.1% | +100bps |
| EBITDA | $3.5B | $3.5B | $29.8B | -0.9% |
| EBITDA Margin | 22.5% | 21.9% | 20.1% | 68bps |
| Net Income | $2.1B | $2.1B | $2.1B | -1.7% |
| Free Cash Flow | $1.8B | $1.9B | $14.2B | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)44.1%
- EBITDA Margin (TTM)20.1%
- Net Margin (TTM)12.6%
- ROIC12.4%
- FCF Conversion40.9%
- SBC / Revenue0.8%
The Company
Ecolab is a global water, hygiene, and infection-prevention company with about $16 billion in annual sales, 48,000 associates, and customers in more than 170 countries and 40 industries. The company says it helps protect one-third of the world's food production and one-quarter of the power generated. Its four reportable segments are Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences.
Revenue mixes product and equipment sales with service and lease income: in Q1 2026, product and equipment sales were $3,174.6 million and service and lease sales were $891.5 million. The company operates a broad, diversified model, and the business does not disclose a meaningful order backlog because much of it is recurring service and consumables.
Business Segments
Competitive Landscape
Management says Ecolab is the only company integrated across chip production water, data-center direct-to-chip liquid cooling, and connected water/energy optimization. The intel file documents Dover as a competitor in thermal/cooling-adjacent equipment and lists Vertiv, Eaton, and Modine as inferred data-center cooling competitors.
- DoverDocumented competitor in thermal/cooling-adjacent equipment; reported sold-out heat-exchanger capacity.
- VertivInferred competitor scaling in data-center thermal management.
- EatonInferred competitor scaling in data-center thermal management.
- ModineInferred competitor scaling in data-center thermal management.
Supply Chain
Ecolab sits between chemical feedstocks and equipment suppliers upstream and industrial, institutional, pharma, semiconductor, and data-center operators downstream. The supplied sources describe tight supply-chain components but do not name individual supplier relationships.
More on ECL: Earnings recap